SCHEMBL7302983

SCHEMBL7302983

CCOC(=O)CC1COc2ccccc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
GAA P10253 1/20 0.46
CYP1A2 P05177 1/20 0.46
MOGAT2 Q3SYC2 2/20 0.44
TSHR P16473 2/20 0.43
HSD17B10 Q99714 2/20 0.43
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPK1 P28482 2/20 0.43
PKM P14618 1/20 0.43
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CASP3 P42574 2/20 0.38
CASP7 P55210 1/20 0.38
CASP8 Q14790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17363665 0.86 GAA (0.48) GAACYP1A2MOGAT2TSHRHSD17B10
SCHEMBL17363918 0.84 KMT2A (0.43) L3MBTL1GAACYP1A2ALDH1A1MEN1
SCHEMBL24776515 0.83 L3MBTL1 (0.46) L3MBTL1CYP1A2ALDH1A1MEN1MAPT
SCHEMBL17363661 0.83 L3MBTL1 (0.46) L3MBTL1CYP1A2ALDH1A1MEN1MAPT
SCHEMBL7298355 0.80 GAA (0.52) GAAMOGAT2HSD17B10ALDH1A1MEN1
SCHEMBL8566723 0.78 TSHR (0.41) L3MBTL1GAACYP1A2TSHRHSD17B10
SCHEMBL8566683 0.78 TSHR (0.41) L3MBTL1GAACYP1A2TSHRHSD17B10
SCHEMBL8566682 0.78 TSHR (0.41) L3MBTL1GAACYP1A2TSHRHSD17B10
SCHEMBL6711082 0.77 CYP1A2 (0.49) GAACYP1A2TSHRHSD17B10ALDH1A1
SCHEMBL11327486 0.77 GAA (0.57) GAAMOGAT2MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0666260-B1 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy SYNTHELABO (FR) 1999-08-04 EP claimed
EP-0614893-B1 Benzoxazine derivatives, their preparation and their use in therapy SYNTHELABO (FR) 1998-05-27 EP claimed
EP-3160948-B1 BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2018-10-24 EP disclosed
US-10017502-B2 Benzoxazinone amides as mineralocorticoid receptor modulators ASTRAZENECA AB (SE) 2018-07-10 US disclosed
US-20170217945-A1 BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2017-08-03 US disclosed
EP-3160948-A1 BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS Astrazeneca AB (SE) 2017-05-03 EP disclosed
EP-2686306-B1 BENZO[B][1,4]OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS LUPIN ATLANTIS HOLDINGS SA (CH) 2017-01-04 EP disclosed
US-9464063-B2 Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators LUPIN ATLANTIS HOLDINGS SA (CH) 2016-10-11 US disclosed
US-9464063-B2 Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators LUPIN ATLANTIS HOLDINGS SA (CH) 2016-10-11 US disclosed
US-9394291-B2 Benzoxazinone amides as mineralocorticoid receptor modulators ASTRAZENECA AB (SE) 2016-07-19 US disclosed
WO-2016001631-A1 BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2016-01-07 WO disclosed
US-8268814-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-8268814-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed
US-20090264400-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-22 US disclosed
US-20090264400-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2009-10-22 US disclosed
WO-2009124746-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2009-10-15 WO disclosed
WO-2009124733-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-10-15 WO disclosed
US-5447928-A Antiischemic agents and nervous system disorders SYNTHELABO (FR) 1995-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217945-A1 BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS NR3C2, CYP11B1, CYP11B2 L3MBTL1 4884/4885GAA 3448/4885CYP1A2 226/4885
US-10017502-B2 Benzoxazinone amides as mineralocorticoid receptor modulators NR3C2, CYP11B1, CYP11B2 L3MBTL1 4884/4885GAA 3448/4885CYP1A2 226/4885
US-20090275558-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS BDKRB2, BDKRB1, TRPV1 L3MBTL1 4835/4885GAA 3388/4885CYP1A2 1996/4885
US-20090264400-A1 Substituted Sulfonamide Compounds BDKRB1, BDKRB2, TRPV1 L3MBTL1 4855/4885GAA 2852/4885CYP1A2 1494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.